Influenza A

Infectious Diseases
8
Pipeline Programs
6
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Intravenous hyperimmune immunoglobulinPhase 31 trial
Active Trials
NCT02287467CompletedEst. Jun 2018
Cocrystal Pharma
Cocrystal PharmaBOTHELL, WA
2 programs
1
1
CC-42344Phase 21 trial
CC-42344Phase 11 trial
Active Trials
NCT05202379CompletedEst. Mar 2023
NCT06160531CompletedEst. Jul 2024
Vir Biotechnology
Vir BiotechnologyCA - San Francisco
2 programs
1
1
VIR-2482Phase 21 trial
VIR-2482Phase 11 trial
Active Trials
NCT04033406CompletedEst. Nov 2021
NCT05567783TerminatedEst. Aug 2023
Celltrion
CelltrionKorea - Incheon
2 programs
2
CT-P27Phase 21 trial
CT-P27 90 mg/kgPhase 21 trial
Active Trials
NCT02071914Completed81Est. Jun 2014
NCT03511066Terminated228Est. Jun 2018
Genentech
GenentechCA - Oceanside
1 program
1
MHAA4549APhase 21 trial
Active Trials
NCT02623322Completed124Est. Nov 2017
Baebies
BaebiesNC - Durham
1 program
Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infectionsN/A1 trial
Active Trials
NCT05928507UnknownEst. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsIntravenous hyperimmune immunoglobulin
Cocrystal PharmaCC-42344
Vir BiotechnologyVIR-2482
CelltrionCT-P27 90 mg/kg
GenentechMHAA4549A
CelltrionCT-P27
Cocrystal PharmaCC-42344
Vir BiotechnologyVIR-2482
BaebiesDiagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections

Clinical Trials (9)

Total enrollment: 433 patients across 9 trials

NCT02287467Allergy TherapeuticsIntravenous hyperimmune immunoglobulin

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

Start: Jan 2015Est. completion: Jun 2018
Phase 3Completed
NCT06160531Cocrystal PharmaCC-42344

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Start: Nov 2023Est. completion: Jul 2024
Phase 2Completed
NCT05567783Vir BiotechnologyVIR-2482

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Start: Oct 2022Est. completion: Aug 2023
Phase 2Terminated
NCT03511066CelltrionCT-P27 90 mg/kg

A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Start: Dec 2016Est. completion: Jun 2018228 patients
Phase 2Terminated
NCT02623322GenentechMHAA4549A

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Start: Oct 2016Est. completion: Nov 2017124 patients
Phase 2Completed
NCT02071914CelltrionCT-P27

A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model

Start: Feb 2014Est. completion: Jun 201481 patients
Phase 2Completed
NCT05202379Cocrystal PharmaCC-42344

CC-42344 Safety Study in Healthy Participants

Start: Feb 2022Est. completion: Mar 2023
Phase 1Completed
NCT04033406Vir BiotechnologyVIR-2482

Study of VIR-2482 in Healthy Volunteers

Start: Aug 2019Est. completion: Nov 2021
Phase 1Completed
NCT05928507BaebiesDiagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections

FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

Start: Oct 2023Est. completion: Mar 2024
N/AUnknown

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
9h ago
$179K - $237K/yr

Consultor Técnico Vacinas Adulto (Brasília/DF)

GSK
BRA - Distrito Federal - Brasília
22h ago

Production Supervisor/First Line Leader

GSK
USA - North Carolina - Zebulon
22h ago

Community Engagement Account Manager - New Haven

GSK
USA - Connecticut - New Haven
22h ago

Scientist, Protein Purification

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Scientist, Protein Biochemistry

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)